![AAAIPodcastLogo](https://education.aaaai.org/sites/default/files/styles/course_image/public/AAAAI%20Podcast%20Logo%20small%20for%20LMS_2.jpg?itok=xf1gb65C)
Episode 41: 2020 NHLBI Asthma Guidelines: What's New & Different
This is a recorded episode of the AAAAI podcast series, Conversations from the World of Allergy. The host, Dr. David Stukus, will interview Michelle Cloutier, MD FAAAAI about the new changes of the NHLBI EPR-4 asthma guidelines. This includes a historical overview of the NHLBI guidelines and a focus on the similarities and differences between the EPR-3. Dr. Cloutier guides us on a deep dive into the five systematic reviews for the treatment of asthma: immunotherapy, the use of inhaled corticosteroids and long-acting muscarinic antagonists, indoor allergen reduction, bronchial thermoplasty safety and effectiveness, and the clinical utility of fractional exhaled nitric oxide. This episode highlights take away points from these five applications for clinicians to utilize in their practice.
Target Audience
- Allergist/immunologists
- Fellows-in-Training
- Nurses and Nurse Practitioners
- Physician Assistants and Other Allied Health Professionals
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the differences between the changes in the NHLBI EPR-3 and NHLBI EPR-4 asthma guidelines
- Identify the different indoor allergen reduction measures
- Select appropriate treatment options for the use of intermittent inhaled costicosteriods and long-acting muscarinic antagonist in a clinical context
- Decide which patients may be candidates for bronchial thermoplasty based on published effectiveness and safety
Planning Committee
David R. Stukus, MD FAAAAI
Nationwide Children's Hospital, Columbus, OH
Relevant relationships: None
Faculty
Michelle Cloutier, MD FAAAAI
UCONN Health, Ellington, CT
Relevant relationships: None
Content Reviewers
Samuel Gubernick, DO FAAAAI
Family Allergy, Asthma and Immunology Associates, Largo, FL
Relevant relationships: None
AAAAI DISCLOSURE POLICY
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:
- Employment. Name of employer and job title.
- Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
- Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
- Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
- Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
- Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
- Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.
ACCREDITATION STATEMENT
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
DESIGNATION STATEMENT
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CREDIT CLAIMING PERIOD
Credit claiming for this activity will expire at 11:59 pm on December 2, 2023. Requests to claim credit on or after December 2, 2023 will be subject to an administrative fee.
AAAAI PRIVACY POLICY
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.
QUESTIONS
Activity related questions should be directed to cme@aaaai.org.
Available Credit
- 1.00 AttendanceAttendance credit.
- 1.00 CMECME credit.
Price
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.
Internet Explorer is no longer supported.
You must listen to Episode 41: 2020 NHLBI Asthma Guidelines: What's New & Different before continuing. Return to this window to continue with the assessment and claim credit.